<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353105</url>
  </required_header>
  <id_info>
    <org_study_id>INCOR-1232-09</org_study_id>
    <nct_id>NCT01353105</nct_id>
  </id_info>
  <brief_title>Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion</brief_title>
  <official_title>Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Only about 15% of the potential candidates for lung donation are considered suitable for
      transplantation. A new method for ex vivo lung perfusion (EVLP) has been developed and can be
      used for evaluation and reconditioning of &quot;marginal&quot; and unacceptable lungs. The ´purpose of
      this study is to analyse the executability and safety of ex vivo lung perfusion pulmonary ex
      vivo in marginal donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Donor Inclusion criteria:

        -  Age &lt; 55 years-old;

        -  Smoking history &lt; 20 pack-year;

        -  Clear chest radiograph;

        -  Absence of significant chest trauma;

        -  Absence of purulent secretions and gastric contents at bronchoscopy;

        -  PaO2 &lt; 300 mm Hg (FIO2 1.0, PEEP 5 cmH2O)

      Exclusion criteria:

        -  Lungs presenting PO2 &lt; 400 mmHg after ex vivo lung perfusion
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-days mortality</measure>
    <time_frame>30 days after ex vivo lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory complications (primary graft dysfunction, infection, rejection, bronchiolitis obliterates syndrome)</measure>
    <time_frame>30 days after the ex vivo lung transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12-months survival</measure>
    <time_frame>12 months survival after ex vivo lung transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenation index (PaO2/FiO2)on ICU arrival and 72 hours</measure>
    <time_frame>72 hours after ex vivo lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time</measure>
    <time_frame>30 days after ex vivo lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital and ICU time of stay</measure>
    <time_frame>12 months after ex vivo lung transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-respiratory complications (arrhythmia, renal failure, sepsis)</measure>
    <time_frame>30 days after ex vivo lung transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>Ex vivo lung transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-group studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ex vivo lung transplantation</intervention_name>
    <description>Evaluation and reconditioning of lungs following lung transplantation</description>
    <arm_group_label>Ex vivo lung transplantation</arm_group_label>
    <other_name>Non applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 55 years-old;

          -  Smoking history &lt; 20 pack-year;

          -  Clear chest radiograph;

          -  Absence of significant chest trauma;

          -  Absence of purulent secretions and gastric contents at bronchoscopy;

          -  PaO2 &lt; 300 mm Hg (FIO2 1.0, PEEP 5 cmH2O)

        Exclusion Criteria:

          -  Lungs presenting PO2 &lt; 400 mmHg after ex vivo lung perfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio B Jatene, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio B Jatene, PhD</last_name>
    <phone>+55-11-3069-5197</phone>
    <email>fabiojatene@incor.usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paulo M Pego-Fernandes, PhD</last_name>
    <phone>+55-11-3069-5922</phone>
    <email>paulopego@incor.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INCOR - Heart Institute</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio B Jatene, PhD</last_name>
      <phone>+55-11-30695197</phone>
      <email>fabiojatene@incor.usp.br</email>
    </contact>
    <investigator>
      <last_name>Fabio B Jatene, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>May 11, 2011</last_update_submitted>
  <last_update_submitted_qc>May 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fabio Biscegli Jatene/ Full Professor of Thoracic Surgery - Medical School, University of São Paulo</name_title>
    <organization>InCor Heart Institute</organization>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

